Government Publications

The units for reporting HbA1c have been updated from percentage (%) to millimoles per mole (mmol/mol) since the release of this guidance. The NICE Pathway on diabetes has been adjusted accordingly.

Is this guidance current? NICE assessed the evidence in May 2011 and found no new information that alters the recommendations provided in the below guidance.

Next assessment: NICE will review this guidance if there is fresh evidence that is likely to impact their recommendations.

This guidance was developed using the NICE multiple technology appraisal process. It is important to note that this guidance supersedes the previous recommendations set forth in ‘The clinical effectiveness and cost-effectiveness of insulin pump therapy’ (NICE technology appraisal guidance 57) issued in February 2003. The updated guidance reflects the latest advancements and best practices in insulin pump therapy for individuals with type 1 diabetes.

Click here to read the NICE guidelines.